Epigenetic anticancer agents cause HMGB1 release in vivo

Peng Liu; Liwei Zhao; Friedemann Loos; Kristina Iribarren; Oliver Kepp; Guido Kroemer

doi:10.1080/2162402X.2018.1431090

Epigenetic anticancer agents cause HMGB1 release in vivo

Oncoimmunology. 2018 Feb 14;7(6):e1431090. doi: 10.1080/2162402X.2018.1431090. eCollection 2018.

Authors

Peng Liu^{1

2

3

4

5

6}, Liwei Zhao^{1

2

3

4

5

6}, Friedemann Loos^{2

3

4

5

6}, Kristina Iribarren^{2

3

4

5

6}, Oliver Kepp^{2

3

4

5

6}, Guido Kroemer^{2

3

4

5

6

7

8}

Affiliations

¹ Faculty of Medicine, University of Paris Sud, Kremlin-Bicêtre, France.
² Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.
³ Equipe 11 labellisée Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France.
⁴ Institut National de la Santé et de la Recherche Médicale, U1138, Equipe labellisée Ligue Nationale Contre le Cancer, Villejuif, France.
⁵ Université Paris Descartes, Sorbonne Paris Cité, Paris, France, Paris, France.
⁶ Université Pierre et Marie Curie, Paris, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France.
⁷ Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.
⁸ Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden.

Abstract

A systematic search for anticancer agents that may induce the release of high mobility group box 1 (HMGB1) protein from cells into the extracellular space has led to the identification of several drugs capable of elevating plasma HMGB1 levels in vivo, in mice. Such agents include bona-fide immunogenic cell death inducers such as oxaliplatin, as well as a series of epigenetic modifiers, namely azacitidine, decitabine, and suberoylanilide hydroxamic acid (SAHA).

Keywords: RUSH; biotin; cancer; chemotherapy; immunosurveillance.

Publication types

Research Support, Non-U.S. Gov't